Ovarian Cancer: Our Clinical Trials

Here you can find a continually updated listing of Memorial Sloan-Kettering's clinical trials for ovarian cancer. To learn more about a study, choose from the list below.

Showing 22 trials
Title Investigator
A Phase I Study of ABT-888 in Combination with Carboplatin and Gemcitabine in Patients with Advanced Solid Tumors
[Protocol 09-154] 		Bell-McGuinn, Katherine, MD, PhD
A Phase I Study of BKM120 and Olaparib in Patients with High-Grade Serous Ovarian Cancer
[Protocol 12-233] 		Bell-McGuinn, Katherine, MD, PhD
A Phase I Study of BMS-986015 plus BMS-936558 in Patients with Advanced Solid Tumors
[Protocol 12-224] 		Segal, Neil, MD, PhD
A Phase I Study of Carboplatin/Paclitaxel/Bevacizumab and ABT-888 in Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 09-106] 		Bell-McGuinn, Katherine, MD, PhD
A Phase I Study of Pegylated Liposomal Doxorubicin, Carboplatin, and Veliparib in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
[Protocol 12-197] 		Bell-McGuinn, Katherine, MD, PhD
A Phase I Study of VTX-2337 Plus Doxil in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 11-110] 		Bell-McGuinn, Katherine, MD, PhD
A Phase I Study of WT1-Specific T Cells for the Treatment of Patients with Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancers
[Protocol 06-155] 		O'Cearbhaill, Roisin, MB BCh BAO
A Phase I Trial of a New Vaccine (Globo-H-GM2-sTn-TF-Tn) for Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
[Protocol 09-184] 		Sabbatini, Paul, MD
A Phase IB Study of MEK162 plus Paclitaxel in Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 12-192] 		Grisham, Rachel, MD
A Phase II Study of Cabozantinib versus Paclitaxel to Treat Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 13-048] 		Makker, Vicky, MD
A Phase II Study of Ipilimumab after Completion of Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian Cancer with Measurable Residual Disease
[Protocol 12-152] 		Grisham, Rachel, MD
A Phase II Study of MLN8237 (Alisertib) with Paclitaxel versus Paclitaxel Alone in Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 12-100] 		Tew, William, MD
A Phase II Study of Secondary Cytoreduction with and without HIPEC plus Postoperative Chemotherapy for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 12-275] 		Chi, Dennis, MD
A Pilot Study Assessing PET Probes to Detect Cancerous Tissue During Surgery for Recurrent Ovarian Cancer
[Protocol 13-017] 		Chi, Dennis, MD
A Pilot Study Surveying Female Cancer Patients' Preference for Sexual Health Interventions
[Protocol 10-034] 		Carter, Jeanne, PhD
A Prospective Study of Quality of Life in Patients Undergoing Pelvic Exenteration
[Protocol 05-001] 		Chi, Dennis, MD
Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
[Protocol 12-104] 		Tew, William, MD
Clinical Significance of Germline BRCA Mutations
[Protocol 96-051] 		Offit, Kenneth, MD
Electronic Patient-Reported Outcomes from Home in Patients Recovering from Major Gynecologic Cancer Surgery: Measuring Symptoms and Quality of Life
[Protocol 08-155] 		Chi, Dennis, MD
Geriatric Assessment and Nursing Telephone Intervention in Elderly Women with Ovarian Cancer
[Protocol 11-164] 		Tew, William, MD
Online Psychoeducation for Sexual Dysfunction in Cancer Survivors
[Protocol 12-012] 		Carter, Jeanne, PhD
Standard Infusion Carboplatin versus Prophylactic Extended Infusion Carboplatin in the Treatment of Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
[Protocol 10-184] 		O'Cearbhaill, Roisin, MB BCh BAO
Related Topics
Recommended Links

Making An Appointment

Please call us at 866-280-0449, Monday - Friday, 8:30 AM to 5:30 PM, eastern time, to schedule an appointment.

Learn more »

Other Useful Information